Načítá se...
Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc
The development of alternative therapeutic strategies to tumor necrosis factor (TNF)-blocking antibodies for the treatment of inflammatory diseases has generated increasing interest. In particular, selective inhibition of TNF receptor 1 (TNFR1) promises a more precise intervention, tackling only the...
Uloženo v:
| Vydáno v: | MAbs |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6601568/ https://ncbi.nlm.nih.gov/pubmed/30929560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1596512 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|